Maftivimab API Manufacturers

General Description:

Maftivimab, identified by CAS number 2135632-36-7, is a notable compound with significant therapeutic applications. Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high specificity. The chief surface target of EBOV particles is the GP_1,2 glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic (i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection. A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Maftivimab (REGN 3479), (REGN 3471), and (REGN 3470) in equimolar proportions. All three mAbs bind to a distinct portion of the GP_1,2 glycoprotein and collectively provide neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against EBOV infection _in vivo_. INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.

Indications:

This drug is primarily indicated for: Maftivimab is indicated in combination with and for the treatment of _Zaire ebolavirus_ infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for _Zaire ebolavirus_ infection. This combination has not been established as efficacious for any other species within either the _Ebolavirus_ or _Marburgvirus_ genera; special care should be taken to evaluate the susceptibility of circulating _Zaire ebolavirus_ strains before beginning treatment, and the possible emergence of resistance should be monitored. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Absorption:

The absorption characteristics of Maftivimab are crucial for its therapeutic efficacy: Maftivimab administered to healthy subjects at 50 mg/kg produced a mean C_max of 1280 ± 68.0 mg/L and a mean AUC_0-∞ of 18,700 ± 4100 mg\*day/L. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Maftivimab is an important consideration for its dosing schedule: Maftivimab administered to healthy subjects at 50 mg/kg has a mean elimination half-life of 22.3 ± 3.09 days. This determines the duration of action and helps in formulating effective dosing regimens.

Volume of Distribution:

Maftivimab is distributed throughout the body with a volume of distribution of: Maftivimab administered to healthy subjects at 50 mg/kg produced a mean steady-state volume of distribution of 57.6 ± 3.89 mL/kg. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Maftivimab is a critical factor in determining its safe and effective dosage: Maftivimab administered to healthy subjects at 50 mg/kg has a mean clearance of 2.78 ± 0.558 mL/day/kg. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Maftivimab exerts its therapeutic effects through: Maftivimab is a fully-humanized IgG1κ monoclonal antibody (mAb) directed against the GP_1,2 glycoprotein that provides strong neutralizing activity against _Zaire ebolavirus_. As a mAb, maftivimab exhibits low toxicity and is generally well tolerated but does include the risk of potentially life-threatening hypersensitivity reactions. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Maftivimab functions by: Ebola virus (EBOV) is one of several viruses within the _Ebolavirus_ genus known to infect humans with an average case fatality rate of 43.92%. EBOV particles expose the GP_1,2 glycoprotein on their surface, which comprises a trimer of GP₁ and GP₂ subunit heterodimers, with the subunits connected by a disulfide bond. GP_1,2 plays an important role in both cell surface attachment/entry and eventual lysosomal escape through binding to the NPC intracellular cholesterol transporter 1/Niemann-Pick C1 protein (NPC1). In this manner, GP_1,2 is integral to the pathogenic cycle of EBOV. Maftivimab is a fully-humanized IgG1κ monoclonal antibody (mAb) directed against the EBOV GP_1,2 glycoprotein, which binds between GP1 and GP2 protomers at the base of the GP_1,2 protein with a binding affinity (_K_D_) of between 2.97 and 3.34 nM. Maftivimab exhibits strong neutralization of chimeric lentiviral particles expressing EBOV GP_1,2 with a half-maximal inhibitory concentration (IC₅₀) value or 0.17 nM, but lacks the ability to induce FcγRIIIa signalling in effector cells. Combined with and , Maftivimab works to block EBOV cell infection and lysosomal escape, as well as the potential antibody-dependent cell-mediated killing of EBOV-infected cells. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Classification:

Maftivimab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.

Categories:

Maftivimab is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Anti-Infective Agents, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antiviral Agents, Blood Proteins, Globulins, Immunoglobulins, Immunoproteins, Proteins, Serum Globulins, Treatments for Ebola Virus Disease. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Maftivimab include:

• Molecular Weight: 143948.11
• Molecular Formula: C6368H9886N1706O2008S46